Home > Boards > US Listed > Medical - Drugs > Medicis Pharmaceutical (MRX)

SCOTTSDALE, Ariz. (AP) - Medicis Pharmaceutical Corp., a

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
Investorman Member Profile
Member Level 
Followed By 48
Posts 19,240
Boards Moderated 0
Alias Born 04/02/01
160x600 placeholder
Investorman Member Level  Tuesday, 09/06/05 11:54:59 AM
Re: None
Post # of 149 
SCOTTSDALE, Ariz. (AP) - Medicis Pharmaceutical Corp., a maker of acne and skin medications, on Thursday reported fiscal fourth-quarter profit rose 3 percent as the cost of planning an acquisition largely offset sales growth.

Net income edged higher to $24.4 million, or 38 cents per share, from $23.7 million, or 34 cents per share, in the year-ago quarter. The latest results are based on 68.9 million shares outstanding versus 74.1 million a year ago.

Related newsDow Closes Down 12 Amid Hurricane Woes Medicis Reports Fourth Quarter and Year-End Fiscal 2005 Financial Results Market Report -- In Play (MRX) Market Report -- In Play (APSG, CAO, ESL, FNSR, HRB, JDSU, KWD, MRX, NWRE, TUTR, SNDS, METH) JoS. A. Bank Clothiers' Second Quarter Earnings Per Share Increase 54%; Company Raises Full Year Earnings Guidance Again
Without a $3.4 million charge related to planning the company's proposed merger with Inamed Corp., Medicis said it earned $27.8 million, or 43 cents per share.

Analysts polled by Thomson Financial expected earnings, excluding one-time charges, of 41 cents per share.

Revenue grew to $100.5 million, up 14 percent from $88 million in the prior-year period, to top the consensus estimate of $99.6 million. Sales of Restylane and Plexion cleansing cloths and the launch of the Vanos psoriasis treatment boosted results, Medicis said.

For the year, net income more than doubled to about $65 million, or $1.01 per share, from $30.8 million, or 52 cents per share.

The results for fiscal 2005 include expenses of $27.8 million associated with research and development collaborations and the $3.4 million merger-planning charge. Excluding those costs, the company earned $96.2 million, or $1.45 per share. Year-ago results included a $37.5 million debt extinguishment charge and $1.6 million in research and development costs.

Full-year revenue expanded 24 percent to $376.9 million from $303.7 million. Analysts predicted income of $1.44 per share on $376 million in sales.

The company said it spent 59 percent more on research and development in 2005 and plans to continue that focus in 2006.




Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist